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CD56+ T CELLS CO-EXPRESSING A CD56-SPECIFIC CHIMERIC ANTIGEN
RECEPTOR CAN TARGET CD56+ MALIGNANCIES WITHOUT AUTOLYSIS
Kellar, D.1, Ang, S.1, Olivares, S.1, Dawson, M.1, Figliola, M.1,
Huls, H.1, Lee, D.1, Champlin, R.2, Cooper, L.1 1University of Texas
M.D. Anderson Cancer Center, Houston, TX; 2University of Texas
M.D. Anderson Cancer Center, Houston, TX
Some candidate tumor antigens are expressed on T cells, which can
preclude development of tumor-specific T-cell based therapies against
these antigens. One such antigen is CD56 which is expressed by many
aggressive malignancies such as neuroblastoma (NBL) and NK-cell
leukemia making this cell-surface molecule an attractive target. How-
ever, expression of CD56 on a subset of T cells may preclude targeting
this self antigen. Recognizing that effector T cells can exhibit cytotox-
icity without damaging themselves, we tested the hypothesis that we
can target a self antigen on tumor cells that is also expressed on tu-
mor-specific T cells. We developed a second generation chimeric an-
tigen receptor (CAR, designated CD56RCD28) to redirect T-cell
specificity to CD56 and evaluated tumor cytotoxicity as well as capac-
ity for fratricide to self CAR+CD56+ T cells. Primary human T cells
were electrotransfered with the CD56RCD28 CAR using the Sleeping
Beauty transposon/transposase system and CAR+ T cells were selec-
tively propagated on g-irradiated CD56+ artificial antigen presenting
cells (aAPCs, added every 7 days) in the presence of exogenous re-
combinant human IL-2 and IL-21. We were able to numerically ex-
pand T cells in tissue culture such that approximately 100%
expressed CAR in both effector and memory T-cell populations. We
demonstrated CD56-specific cytotoxicity against CD56+ allogenic
NBL cells and also against autologous unmanipulated CD3+CD56+ T
cells and CD3negCD56+ NK-cells (TABLE). Surprisingly, the CAR+
T cells maintained a sub-population of CAR+CD56+ T cells at a per-
centage similar to those observed when propagating CD19-specific
CAR+ T cells on CD19+ aAPC. Upon evaluating the ability of CAR+
T cells to target autologousCAR+CD56+ T cells (evaluating fratricide)
we demonstrated no autolytic cytotoxicity (TABLE). The CAR+ T
cells were sorted into a purified CAR+CD56+ population which was
numerically expanded on aAPCs. These CAR+CD56+ T cells main-
tained expression ofCD56+ over the culture period. In aggregate, these
data demonstrate that CAR+CD56+ T cells are resistant to CD56-
specifc CAR-mediated self lysis. These data may enable the develop-
ment of CD56-specific CAR for cancer therapies and show that target-
ing a self-antigen expressed on theT-cell surface is not an impediment
to the ability of CAR+ T cells to target tumor cells.Redirected Cytotoxicity by CD56-Specific T Cells
Target Cells Specific Lysis (% [51]Cr Release)
CD56neg K562 Parental 2.5
CD561 Neuroblastoma SK-N-BE(2) 41.1
Autologous CD31CD561 T cells 25.8
Autologous CD3negCD561 NK cells 22.6
Autologous CAR1CD561 T cells 0
Autologous CAR1CD56neg T cells 0
CD56RCD28 CAR1 T cells as effectors against multiple chromium-
labeled targets.2
IDENTIFICATION OF A CLONOGENIC OSTEOCHONDRAL SKELETAL PRO-
GENITORWHICH FORMS THE FUNCTIONAL HEMATOPOIETIC STEM CELL
NICHE
Chan, C., Kraft, D., Ching, C., Jill, H., Irving, W., Longaker, M. Stan-
ford UniversityThe local ‘‘niche’’micro-environment is essential for stem-cellmain-
tenance and hematopoiesis.We recently developed an in vivo assay for
adult murine haematopoietic stem-cell (HSC) niche formation
(Nature, 2009). With this assay, we identified a population of progen-
itor cells identified with surface markers CD45(-)Tie2(-)
alpha(V)(+)CD105(+)Thy1.1(-) (CD105(+)Thy1(-)) that, when sorted
from 15.5 days post-coitum fetal bones and transplanted under the
adult mouse kidney capsule, could recruit host-derived blood vessels,
produce donor-derived ectopic bones through a cartilage intermediate
and generate a marrow cavity populated by host-derived long-term
reconstituting HSC (LT-HSC). In contrast, CD45(-)Tie2(-)
alpha(V)(+)CD105(+)Thy1(+) (CD105(+)Thy1(+)) fetal bone progeni-
tors form bone that does not contain a marrow cavity. In subsequent
work we have demonstrate the ability of the sorted CD45-Tie2-aV+
niche progenitor to expand and support fully functional HSC mainte-
nance in-vitro. CD45-Tie2-aV+ skeletal progenitors are detectable at
embryonic 12.5dpc,up toadulthood and canbe further subfractionated
into three functionally distinct populations based on expression of
CD105andThy1.Only lownumbers of skeletal progenitors aredetect-
able in adult bone tissue but we find that BMP2, which is abundantly
expressed in adult bones, could induce denovo formation of osteogenic
skeletal progenitors. In summarywehave isolated a clonogenic skeletal
progenitorwhose progeny include chondrocytes and osteoblasts.We
also find evidence that thesemature progeny could directly induce de
novo formation of new osteochondral progenitors from non-osseous
tissue by means of BMP signaling. This work and assay system forms
the basis for ongoing identification of the human equivilant progen-
itor populations.3
DERIVATION AND EXPANSION OF NEURAL STEM CELL (NSC) LIKE CELLS
FROM HUMAN UMBILICAL CORD BLOOD (HUCB)
Liao, Y.1, Baxi, L.2, Mitchell, K.1, Ayello, J.1, van de Ven, C.1,
Cairo, M.S.1,3,4 1Columbia University, Morgan Stanley Children’s Hos-
pital of New York Presbyterian, NY; 2Columbia University, New York,
NY; 3Columbia University, New York, NY; 4Columbia University,
New York, NY
Background: Neural stem cells (NSCs) have been widely explored
in stem cell based therapies for a variety of neurological diseases.
However, the acquisition of human NSCs in both high purity and
large quantity is an absolute requirement and current derivation of
NSCs, either from embryonic stem cells or fetal tissues, is restricted
by a series of challenges such as safety (teratoma development), avail-
ability, and ethical considerations. Therefore, alternative stem cell
sources that circumvent such problems are in great demand. We
and the others have successfully utilized human UCB as an alterna-
tive source for allogeneic hematopoietic progenitor cells for a variety
of malignant and nonmalignant diseases. UCB has also been utilized
successfully to treat neurodegenerative diseases such as Krabbe’s dis-
ease and Hurler’s syndrome. Recently, we and others demonstrated
that UCB also contains pluripotent cells that are capable of differen-
tiation into cells representative of all three embryonic germ layers.
Objective: To isolate, purify and characterize NSCs from HUCB.
Methods:Unrestricted somatic stem cells (USSCs) were initiated by
platingHUCBmononuclear cells in the high serum (30%FBS) in the
presence of 1027 Mdexamethasone. After the initial appearance of fi-
broblast like colonies, cells were expanded in the samemediumwith-
out dexamethasone. To induce neural differentiation, USSCs were
plated in laminin-coated plastic in serum free medium the presence
of EGF and FGF2. To enrich for neural stem cells, cells wereS153
